Roughly 6 months after starting tezepelumab for severe asthma, many patients reduced OCS dependence and meaningfully improved ...

In the WAYFINDER trial, tezepelumab reduced oral corticosteroid use in patients with severe asthma, with well-controlled ...

Patients who depended on oral corticosteroids to care for their severe asthma experienced improvements in asthma control ...

Adult asthma affects more than 25 million Americans, yet many sufferers unknowingly engage in daily practices that exacerbate their condition. Unlike childhood asthma, which often receives immediate ...

Patients with obesity and asthma who used GLP-1 receptor agonists had significantly fewer exacerbations and prednisone use ...

Asthma clinical remission among patients taking dupilumab is most likely to occur in those with increased baseline BEC and FeNO levels.

Asthma patients who use Teva Pharmaceutical’s Digihaler System are more likely to improve control of their condition than their counterparts who use standard-of-care albuterol inhalers, a 12-week ...

In the VOYAGE trial, dupilumab (Dupixent) significantly reduced asthma exacerbations and improved lung function and asthma control in children (ages 6 to 11 years) with uncontrolled, ...

Each patient using inhalers with propellants in 2023 produced 140kg of CO2 emissions over a year. Read more at ...

WASHINGTON -- Adding dupilumab (Dupixent) to a medium-dose inhaled corticosteroid (ICS) routine helped lower asthma exacerbations and improved both lung function and asthma control, according to a ...